Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab

BACKGROUND: Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection...

Descripción completa

Detalles Bibliográficos
Autores principales: So, Wonhee, Pandya, Shuchi, Quilitz, Rod, Shah, Bijal, Greene, John N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937972/
https://www.ncbi.nlm.nih.gov/pubmed/29755706
http://dx.doi.org/10.4084/MJHID.2018.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937972/
https://www.ncbi.nlm.nih.gov/pubmed/29755706
http://dx.doi.org/10.4084/MJHID.2018.029

Ejemplares similares